| |
| |
|
| Insider
Information: |
Silvernail Lauren P |
| Relationship: |
|
| City: |
Irvine |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
207,068 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,016,525 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
207,068 |
|
|
| Total
Value |
$2,016,525 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -60.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
ISTA Pharmaceuticals Inc |
ISTA |
CFO & VP Corporate Dev... |
2012-06-06 |
0 |
2005-05-12 |
0 |
Premium* |
|
|
Revance Therapeutics, Inc. |
RVNC |
CFO & CBO |
2018-05-22 |
65,497 |
2014-05-19 |
0 |
Premium* |
|
|
Evolus Inc |
EOLS |
See Remarks |
2022-05-18 |
141,571 |
2018-05-29 |
0 |
Premium* |
|
|
Harpoon Therapeutics, Inc. |
HARP |
|
2024-03-11 |
0 |
2023-11-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2022-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
53,571 |
219,967 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2022-03-08 |
4 |
AS |
$9.73 |
$99,121 |
D/D |
(10,192) |
209,775 |
0 |
% |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2021-08-10 |
4 |
S |
$11.18 |
$159,774 |
D/D |
(14,293) |
194,982 |
0 |
% |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2022-05-17 |
4 |
S |
$13.92 |
$225,354 |
D/D |
(16,189) |
193,586 |
0 |
% |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-05-08 |
4 |
OE |
$1.04 |
$731,653 |
D/D |
145,813 |
186,681 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-05-08 |
4 |
D |
$9.08 |
$731,639 |
D/D |
(80,577) |
185,020 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2021-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
180,689 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2021-08-10 |
4/A |
AS |
$11.18 |
$159,774 |
D/D |
(14,293) |
166,396 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2022-05-18 |
4 |
S |
$12.42 |
$646,026 |
D/D |
(52,015) |
141,571 |
0 |
% |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2011-11-30 |
4 |
A |
$0.00 |
$27 |
D/D |
27,375 |
123,880 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-02-02 |
4 |
D |
$8.18 |
$7,706 |
D/D |
(942) |
122,938 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-02-03 |
4 |
D |
$8.22 |
$7,743 |
D/D |
(942) |
121,996 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-02-07 |
4 |
D |
$8.17 |
$9,363 |
D/D |
(1,146) |
120,850 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2012-02-08 |
4 |
D |
$8.15 |
$8,688 |
D/D |
(1,066) |
119,784 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
CFO |
• – – |
2011-05-10 |
4 |
OE |
$1.04 |
$195,851 |
D/D |
62,667 |
100,875 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-03-13 |
4 |
OE |
$8.70 |
$225,043 |
D/D |
25,867 |
98,821 |
0 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2011-08-11 |
4 |
B |
$4.28 |
$10,705 |
D/D |
2,500 |
96,505 |
2.74 |
- |
|
| ISTA |
ISTA Pharmaceuticals Inc |
CFO |
• – – |
2011-05-10 |
4 |
D |
$11.26 |
$382,840 |
D/D |
(34,000) |
94,005 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2020-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
93,388 |
0 |
- |
|
| EOLS |
Evolus Inc |
See Remarks |
• – – |
2021-01-25 |
4 |
AS |
$7.46 |
$20,135 |
D/D |
(2,699) |
90,689 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-03-07 |
4 |
OE |
$8.70 |
$87,000 |
D/D |
10,000 |
82,954 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-03-09 |
4 |
OE |
$8.70 |
$87,000 |
D/D |
10,000 |
82,954 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,125 |
74,090 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-02-15 |
4 |
D |
$31.75 |
$36,068 |
D/D |
(1,136) |
72,954 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO, CBO & Secretary |
• – – |
2018-03-07 |
4 |
AS |
$31.50 |
$315,000 |
D/D |
(10,000) |
72,954 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
